Page 138 - MEMOCiberesp014-ENG

RESEARCH GROUPS
Drug Delivery and Targeting Group
Programme: Nanomedicine
Lead Researcher: Schwartz Navarro, Simó Group Members
STAFF MEMBERS: Gener, Petra | Mancilla Zamora, Sandra | Pla Solans, Helena | Santos Benito, Fernando Fidel
ASSOCIATED MEMBERS: Abasolo Olaortua, Ibane | Alijotas Reig, Jaume | Arango Del Corro, Diego | Armengol Carrasco, Manuel | Baldrich Rubio, Eva | Espin Basany, Eloy | Fernández Amurgo, Yolanda | López Cano, Manuel | Sayos Ortega, Juan
CONTRIBUTORS: Andretta, Elena | Bazzocco, Sarah | Ejarque Ortiz, Aroja | García Aranda, Natalia | García Latorre, Laura | Gonçalves Rodrigues, Paulo André | Mougan Albela, Isabel | Pujol Esclusa, Anna | Salas Torras, Anna
Main lines of research
Our group develops research projects mainly focused on oncology and rare diseases .
These projects are conducted around three preferred work areas:
• Area 1: biomarkers and therapeutic targets from suitable experimental models, as molecular biomar- kers, diagnostic providers in biosensors (nanodiagnosis) or for biofunctionalizing new nanomedicines and therapeutic targets for designing new more effective treatments or alternative therapeutic stra- tegies (new nanomedicines) .
• Area 2: experimental chemistry and applied nanotechnology, especially enhancing the study of po- lymeric nanomedicines, through simpler chemical synthesis designs and potential scalability, as well as new experimental genomic therapies (iRNA, artificial non-viral vectors, etc .) and the study of biomedi- cal applications based on nanotechnology (biosensors) and new biomaterials .
• Area 3: Validation of targets and functional studies . This is essential for obtaining concept tests and preclinical studies of new biomarkers and targets, as well as of new nanomedicines including: biodis- tribution, toxicity, therapeutic activity, specificity, functional molecular studies, etc..., in different in vitro and in vivo experimental models .
138 CIBER-BBN » Annual report 2014